CN102131798A - 用作磷酸二酯酶10抑制剂的二取代的苯基化合物 - Google Patents

用作磷酸二酯酶10抑制剂的二取代的苯基化合物 Download PDF

Info

Publication number
CN102131798A
CN102131798A CN2009801332872A CN200980133287A CN102131798A CN 102131798 A CN102131798 A CN 102131798A CN 2009801332872 A CN2009801332872 A CN 2009801332872A CN 200980133287 A CN200980133287 A CN 200980133287A CN 102131798 A CN102131798 A CN 102131798A
Authority
CN
China
Prior art keywords
compound
alkyl
group
cycloalkyl
replaces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801332872A
Other languages
English (en)
Chinese (zh)
Inventor
理查德.切兹沃思
吉迪恩.夏皮罗
埃米.里普卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forum Pharmaceuticals Inc
Original Assignee
EnVivo Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnVivo Phamaceuticals Inc filed Critical EnVivo Phamaceuticals Inc
Publication of CN102131798A publication Critical patent/CN102131798A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2009801332872A 2008-06-25 2009-06-25 用作磷酸二酯酶10抑制剂的二取代的苯基化合物 Pending CN102131798A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7559908P 2008-06-25 2008-06-25
US61/075,599 2008-06-25
US13885608P 2008-12-18 2008-12-18
US61/138,856 2008-12-18
PCT/US2009/048608 WO2009158467A2 (en) 2008-06-25 2009-06-25 Di-substituted phenyl compounds

Publications (1)

Publication Number Publication Date
CN102131798A true CN102131798A (zh) 2011-07-20

Family

ID=41137470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801332872A Pending CN102131798A (zh) 2008-06-25 2009-06-25 用作磷酸二酯酶10抑制剂的二取代的苯基化合物

Country Status (11)

Country Link
US (1) US20110224204A1 (https=)
EP (1) EP2297131A2 (https=)
JP (1) JP2011526294A (https=)
KR (1) KR20110025984A (https=)
CN (1) CN102131798A (https=)
AU (1) AU2009262150A1 (https=)
BR (1) BRPI0914775A2 (https=)
CA (1) CA2729220A1 (https=)
MX (1) MX2011000177A (https=)
RU (1) RU2011102587A (https=)
WO (1) WO2009158467A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323560A (zh) * 2020-08-04 2023-06-23 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5778164B2 (ja) * 2009-10-30 2015-09-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 放射標識ｐｄｅ１０リガンド
EP2423181A1 (en) 2010-07-28 2012-02-29 Prous Institute For Biomedical Research S.A. Multitarget substituted biphenyl diol derivatives
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2014007228A1 (ja) * 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
WO2014009305A1 (en) * 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP2860177A3 (en) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2018170284A1 (en) 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3752498B1 (en) 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
AR116424A1 (es) 2018-09-18 2021-05-05 Crinetics Pharmaceuticals Inc Moduladores de la somatostatina y usos de los mismos
TWI841768B (zh) * 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
KR102811543B1 (ko) 2019-10-16 2025-05-23 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물
EP4294797A1 (en) 2021-02-17 2023-12-27 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
JP2026500913A (ja) 2022-12-13 2026-01-09 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055925A (zh) * 1990-04-19 1991-11-06 帝国化学工业公司 吡啶衍生物及其制备方法
CN1058774A (zh) * 1990-06-19 1992-02-19 明治制菓株式会社 血管紧张素ii拮抗性吡啶衍生物
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US20060122256A1 (en) * 2004-12-03 2006-06-08 Paul Gillespie Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2264710A (en) * 1992-03-04 1993-09-08 Merck & Co Inc Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055925A (zh) * 1990-04-19 1991-11-06 帝国化学工业公司 吡啶衍生物及其制备方法
CN1058774A (zh) * 1990-06-19 1992-02-19 明治制菓株式会社 血管紧张素ii拮抗性吡啶衍生物
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US20060122256A1 (en) * 2004-12-03 2006-06-08 Paul Gillespie Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323560A (zh) * 2020-08-04 2023-06-23 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物
CN116323560B (zh) * 2020-08-04 2026-04-03 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物

Also Published As

Publication number Publication date
KR20110025984A (ko) 2011-03-14
MX2011000177A (es) 2011-06-20
RU2011102587A (ru) 2012-07-27
CA2729220A1 (en) 2009-12-30
US20110224204A1 (en) 2011-09-15
EP2297131A2 (en) 2011-03-23
AU2009262150A1 (en) 2009-12-30
JP2011526294A (ja) 2011-10-06
BRPI0914775A2 (pt) 2015-10-20
WO2009158467A3 (en) 2010-07-29
WO2009158467A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
CN102131798A (zh) 用作磷酸二酯酶10抑制剂的二取代的苯基化合物
CN102131801B (zh) 1,2-二取代的杂环化合物
CA2787360C (en) Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
RU2531274C2 (ru) Феноксиметильные гетероциклические соединения
CN103153996A (zh) 作为激酶抑制剂的喹啉和喹喔啉衍生物
WO2020011246A1 (zh) 含苯环的化合物、其制备方法及应用
US10160762B2 (en) 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
CN111808080B (zh) 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用
CN109305957B (zh) 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用
TW202400167A (zh) 色胺酮衍生物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20110720

C20 Patent right or utility model deemed to be abandoned or is abandoned